Lou 2010.

Methods	Randomized trial Eligible patients Confirmed stage III or IV NSCLC ≥ 70 years of age Measurable or evaluable disease No prior chemotherapy ECOG PS: 0 to 2 Life expectancy ≥ 3 months Adequate bone marrow, renal, and hepatic function No exclusion criteria reported
Participants	G arm: 34 participants ‐ median age (range): 72 (70 to 80) years; 3 participants with PS of 0, 28 with PS of 1, and 3 with PS of 2 CG arm: 34 participants ‐ median age (range): 72 (70 to 77) years; 1 participant with PS of 0, 30 with PS of 1, and 3 with PS of 2
Interventions	G arm: gemcitabine 1000 mg/m2 i.v. infusion on days 1 and 8, every 3 weeks CG arm: carboplatin AUC5 i.v. infusion on day 2 and gemcitabine 1000 mg/m2 i.v. infusion on days 1 and 8, every 3 weeks
Outcomes	Outcomes Overall survival Response rate Toxicity according to WHO criteria QoL assessed by LCSS
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No information on random sequence generation
Allocation concealment (selection bias)	Unclear risk	No information on allocation concealment
Blinding of outcome assessment (detection bias) OS and 1y OS rate outcome	Unclear risk	No information on blinding of outcome assessors for OS and 1yOS. Study considered to have unclear impact on mortality outcomes
Blinding of outcome assessment (detection bias) Other outcomes	High risk	No information on blinding of outcome assessors for other outcomes
Incomplete outcome data (attrition bias) All outcomes	Low risk	No evidence of attrition bias. No loss to follow‐up
Selective reporting (reporting bias)	Low risk	No evidence of selective reporting bias
Other bias	Low risk	No evidence of other bias